NeOnc Technologies (NTHI) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verrica Pharmaceuticals (VRCA) has outperformed NeOnc Technologies (NTHI) over the past year, losing 5.4% versus a loss of 79.1%. NeOnc Technologies is the larger company by market cap ($80.9 million vs $73.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | VRCA |
|---|---|---|
| Share price | $2.81 | $4.26 |
| Market cap | $80.94M | $73.18M |
| 1-day change | +11.16% | +1.91% |
| YTD return | -69.41% | -49.70% |
| 1-year return | -79.07% | -5.43% |
| 5-year return | — | -96.87% |
| EPS (TTM) | $-2.13 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $9.82 |
| 52-week low | $2.50 | $3.28 |
| Distance from 52-week high | -76.76% | -56.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +504.98% | +224.66% |
| Average volume | 195.17K | 62.56K |
| Shares outstanding | 28.81M | 17.18M |
| Employees | 5 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRCA has outperformed NTHI by 73.6 percentage points over the past year.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
NTHI vs VRCA FAQ
Which is bigger, NeOnc Technologies or Verrica Pharmaceuticals?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $80.94M compared with $73.18M for Verrica Pharmaceuticals (VRCA).
Which stock has performed better over the past year, NTHI or VRCA?
VRCA returned -5.43% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and Verrica Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.